secwatch.observer — SEC 8-K summary
======================================

Issuer:     GALECTIN THERAPEUTICS INC (GALT)
CIK:        0001133416
Form:       8-K
Filed at:   2023-01-05T23:59:59+00:00
Accession:  0001140361-23-000580
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Galectin completes enrollment in NAVIGATE Phase 2b/3 belapectin study for NASH cirrhosis
--------------------------------------------------------------------------------

- 309 patients randomized to date; expects 325-340 total by early March 2023.
- Phase 2b portion studies belapectin 2 mg/kg and 4 mg/kg vs. placebo (1:1:1).
- Primary endpoint: primary prevention of esophageal varices in NASH cirrhosis with portal hypertension.
- Interim analysis results expected in Q4 2024 after 18-month treatment period.
- Study recruited patients across 14 countries and five continents.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1133416/000114036123000580/0001140361-23-000580-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1133416/000114036123000580/brhc10046311_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-000580

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer